MSD and AstraZeneca report positive topline data from Koselugo trial for NF1
Merck & Co (MSD), Alexion, and AstraZeneca Rare Disease have reported positive topline outcomes from the Phase III KOMET ...
Business Wire20h
Pimicotinib Significantly Improved Outcomes for Patients with Tenosynovial Giant Cell Tumor in a Global Phase III Trial
Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD ...
Seeking Alpha3h
Sanofi: Diverse Drug Portfolio And Future Pipeline, 4% Dividend Yield Looks Attractive
With a diverse drug portfolio and a robust pipeline of future drugs to market, this big pharma brand will play a major role ...
PharmiWeb21h
Cosmos Health Issues Letter to Shareholders
CHICAGO, IL / ACCESSWIRE / November 12, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a ...
Cosmos Health Inc.: Cosmos Health Issues Letter to Shareholders
CHICAGO, IL / ACCESSWIRE / November 12, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company') (NASDAQ:COSM), a ...
Le Lézard18m
Nobel Laureate Biochemist Dr. James Rothman Joins Deep Tech VC Firm Celesta Capital
Celesta Capital, a global deep tech venture capital firm, today announced it is welcoming 2013 Nobel Laureate Dr. James Rothman as a Senior Advisor. Dr. Rothman will apply his expertise as a ...